Patents by Inventor Ian Clark-Lewis
Ian Clark-Lewis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20110230422Abstract: A use of a composition comprising an SDF-1 peptide having the sequence KGVSLSYR is taught. The composition can be used to purge an ex vivo hematopoietic stem cell culture of cancer cells for engraftment in a mammal by administering the composition to the ex vivo hematopoietic stem cell culture in an effective amount.Type: ApplicationFiled: December 23, 2009Publication date: September 22, 2011Inventors: Christopher R. Tudan, Ahmed Merzouk, Lakhdar Arab, Geeta Saxena, Connie J. Eaves, Joanne Cashman, Ian Clark-Lewis, Mary A. Richter, Michael Clark-Lewis, Hassan Salari
-
Publication number: 20110118193Abstract: A use of a composition comprising an SDF-1 peptide having the sequence KGVSLSYR is taught. The composition can be used in the manufacture of a medicament for the treatment of a blood cancer in a mammal by administering the medicament in a therapeutically effective amount.Type: ApplicationFiled: December 23, 2009Publication date: May 19, 2011Inventors: Christopher R. Tudan, Ahmed Merzouk, Lakhdar Arab, Geeta Saxena, Connie J. Eaves, Joanne Cashman, Ian Clark-Lewis, Mary A. Richter, Michael Clark-Lewis, Hassan Salari
-
Publication number: 20090192082Abstract: Compositions comprising a peptide consisting of an amino acid sequence derived from a P2G-substituted SDF-1 protein are taught. The amino acid sequence consists of a first sequence consisting of 8 to 17 amino acids from the N-terminal portion of the SDF-1 protein and having a conserved KGVS motif. The amino acid sequences may also consist of one or more optional components selected from the group consisting of a second sequence consisting of 8 to 17 amino acids from the N-terminal portion of the SDF-1 protein and having a conserved KGVS motif, wherein the second sequence is covalently joined to the first sequence with or without a linker; and, a third sequence consisting of LKWIQEYLEKALN, or conservative substitutions thereof, wherein the third sequence is covalently joined to the first sequence with the linker. Methods of increasing multiplication of hematopoietic cells and enhancing proliferation of hematopoietic cells during engraftment are also taught.Type: ApplicationFiled: August 11, 2008Publication date: July 30, 2009Inventors: Christopher R. Tudan, Ahmed Merzouk, Lakhdar Arab, Geeta Saxena, Connie J. Eaves, Joanne Cashman, Ian Clark-Lewis, Hassan Salari, Mary A. Richter, Michael Clark-Lewis
-
Patent number: 7435718Abstract: In accordance with various aspects of the invention, CXCR4 antagonists may be used to treat hematopoietic cells, such as progenitor or stem cells, to promote the rate of cellular multiplication, self-renewal, proliferation or expansion. CXCR4 antagonists may be used therapeutically to stimulate hematopoietic stem/progenitor cell multiplication/self-renewal.Type: GrantFiled: September 20, 2004Date of Patent: October 14, 2008Assignees: Chemokine Therapeutics Corp., The University of British ColumbiaInventors: Christopher R. Tudan, Ahmed Merzouk, Lakhdar Arab, Geeta Saxena, Connie J. Eaves, Johanne Cashman, Mary A. Richter, legal representative, Michael Clark-Lewis, legal representative, Hassan Salari, Ian Clark-Lewis
-
Patent number: 7423011Abstract: The invention provides a variety of therapeutic uses for CXCR4 antagonists. In various embodiments, CXCR4 antagonists may be used as therapeutically as follows, or to manufacture a medicament for such therapeutic treatments: reducing interferon gamma production by T-cells, treatment of an autoimmune disease, treatment multiple sclerosis, treatment of cancer, inhibition of angiogenesis. The invention provides corresponding methods of medical treatment, in which a therapeutic dose of a CXCR4 antagonist is administered in a pharmacologically acceptable formulation. Accordingly, the invention also provides therapeutic compositions comprising a CXCR4 antagonist and a pharmacologically acceptable excipient or carrier. The CXCR4 antagonists for use in the invention may be peptide compounds comprising a substantially purified peptide fragment, modified fragment, analogue or pharmacologically acceptable salt of SDF-1.Type: GrantFiled: May 23, 2005Date of Patent: September 9, 2008Assignee: The University of British ColumbiaInventors: Ian Clark-Lewis, Jiang-Hong Gong, Vincent Duronio
-
Patent number: 7378098Abstract: In accordance with various aspects of the invention, CXCR4 agonists, including SDF-1 polypeptides and SDF-1 polypeptide homologues, may be used in reducing the rate of hematopoietic cell multiplication. Methods of the invention may comprise administration of an effective amount of an CXCR4 agonist to cells selected from the group consisting of hematopoietic stem cells and hematopoietic progenitor cells. Cells may be treated in vitro or in vivo in a patient. A therapeutically effective amount of the CXCR4 agonist may be administered to a patient in need of such treatment. Patients in need of such treatments may include, for example patients requiring bone marrow or peripheral blood stem cell transplantation.Type: GrantFiled: February 26, 2002Date of Patent: May 27, 2008Assignees: The University of British Columbia, Chemokine Therapeutics CorporationInventors: Christopher R. Tudan, Ahmed Merzouk, Lakhdar Arab, Geeta Saxena, Connie J. Eaves, Johanne Cashman, Ian Clark-Lewis, Hassan Salari
-
Patent number: 7354899Abstract: The invention provides a variety of therapeutic uses for CXCR4 antagonists. In various embodiments, CXCR4 antagonists may be used as therapeutically as follows, or to manufacture a medicament for such therapeutic treatments: reducing interferon gamma production by T-cells, treatment of an autoimmune disease, treatment of multiple sclerosis, treatment of cancer, inhibition of angiogenesis. The invention provides corresponding methods of medical treatment, in which a therapeutic dose of a CXCR4 antagonist is administered in a pharmacologically acceptable formulation. Accordingly, the invention also provides therapeutic compositions comprising a CXCR4 antagonist and a pharmacologically acceptable excipient or carrier. The CXCR4 antagonists for use in the invention may be peptide compounds comprising a substantially purified peptide fragment, modified fragment, analogue or pharmacologically acceptable salt of SDF-1.Type: GrantFiled: February 16, 2005Date of Patent: April 8, 2008Assignee: The University of British ColumbiaInventors: Ian Clark-Lewis, Jiang-Hong Gong, Vincent Duronio, Hassan Salari
-
Publication number: 20060014682Abstract: In accordance with various aspects of the invention, CXCR4 antagonists may be used to treat hematopoietic cells, such as progenitor or stem cells, to promote the rate of cellular multiplication, self-renewal, proliferation or expansion. CXCR4 antagonists may be used therapeutically to stimulate hematopoietic stem/progenitor cell multiplication/self-renewal.Type: ApplicationFiled: September 20, 2004Publication date: January 19, 2006Applicants: Chemokine Therapeutics Corporation, The University of British ColumbiaInventors: Christopher Tudan, Ahmed Merzouk, Lakhdar Arab, Geeta Saxena, Connie Eaves, Joanne Cashman, Ian Clark-Lewis, Hassan Salari, Michael Clark-Lewis
-
Publication number: 20050265969Abstract: The invention provides a variety of therapeutic uses for CXCR4 antagonists. In various embodiments, CXCR4 antagonists may be used as therapeutically as follows, or to manufacture a medicament for such therapeutic treatments: reducing interferon gamma production by T-cells, treatment of an autoimmune disease, treatment multiple sclerosis, treatment of cancer, inhibition of angiogenesis. The invention provides corresponding methods of medical treatment, in which a therapeutic dose of a CXCR4 antagonist is administered in a pharmacologically acceptable formulation. Accordingly, the invention also provides therapeutic compositions comprising a CXCR4 antagonist and a pharmacologically acceptable excipient or carrier. The CXCR4 antagonists for use in the invention may be peptide compounds comprising a substantially purified peptide fragment, modified fragment, analogue or pharmacologically acceptable salt of SDF-1.Type: ApplicationFiled: May 23, 2005Publication date: December 1, 2005Applicant: The University of British ColumbiaInventors: Ian Clark-Lewis, Jiang-Hong Gong, Vincent Duronio
-
Patent number: 6946445Abstract: The invention provides a variety of therapeutic uses for CXCR4 antagonists. In various embodiments. CXCR4 antagonsits may be used as therapeutically as follows, or to manufacture a medicament for such therapeutic treatments: reducing interferon gamma production by T-cells, treatment of an autoimmune disease, treatment multiple sclerosis, treatment of cancer, inhibition of angiogenesis. The invention provides corresponding methods of medical treatment, in which a therapeutic dose of a CXCR4 antagonist is administered in a pharmacologically acceptable formulation. Accordingly, the invention also provides therapeutic compositions comprising a CXCR4 antagonist and a pharmacologically acceptable excipient or carrier. The CXCR4 antagonists for use in the invention may be peptide compounds comprising a substantially purified peptide fragment, modified fragment, analogue or pharmacologically acceptable salt of SDF-1.Type: GrantFiled: March 12, 1999Date of Patent: September 20, 2005Assignee: The University of British ColumbiaInventors: Ian Clark-Lewis, Jiang-Hong Gong, Vincent Duronio
-
Publication number: 20050164935Abstract: The invention provides a variety of therapeutic uses for CXCR4 antagonists. In various embodiments, CXCR4 antagonists may be used as therapeutically as follows, or to manufacture a medicament for such therapeutic treatments: reducing interferon gamma production by T-cells, treatment of an autoimmune disease, treatment of multiple sclerosis, treatment of cancer, inhibition of angiogenesis. The invention provides corresponding methods of medical treatment, in which a therapeutic dose of a CXCR4 antagonist is administered in a pharmacologically acceptable formulation. Accordingly, the invention also provides therapeutic compositions comprising a CXCR4 antagonist and a pharmacologically acceptable excipient or carrier. The CXCR4 antagonists for use in the invention may be peptide compounds comprising a substantially purified peptide fragment, modified fragment, analogue or pharmacologically acceptable salt of SDF-1.Type: ApplicationFiled: February 16, 2005Publication date: July 28, 2005Applicant: The University of British Columbia of Industry Liaison OfficeInventors: Ian Clark-Lewis, Jiang-Hong Gong, Vincent Duronio, Hassan Salari
-
Patent number: 6875738Abstract: The invention provides a variety of therapeutic uses for CXCR4 antagonists. In various embodiments, CXCR4 antagonists may be used as therapeutically as follows, or to manufacture a medicament for such therapeutic treatments: reducing interferon gamma production by T-cells, treatment of an autoimmune disease, treatment of multiple sclerosis, treatment of cancer, inhibition of angiogenesis. The invention provides corresponding methods of medical treatment, in which a therapeutic dose of a CXCR4 antagonist is administered in a pharmacologically acceptable formulation. Accordingly, the invention also provides therapeutic compositions comprising a CXCR4 antagonist and a pharmacologically acceptable excipient or carrier. The CXCR4 antagonists for use in the invention may be peptide compounds comprising a substantially purified peptide fragment, modified fragment, analogue or pharmacologically acceptable salt of SDF-1.Type: GrantFiled: August 16, 1999Date of Patent: April 5, 2005Assignee: The University of British Columbia of Industry Liaison OfficeInventors: Ian Clark-Lewis, Jiang-Hong Gong, Vincent Duronio, Hassan Salari
-
Publication number: 20030148940Abstract: In accordance with various aspects of the invention, CXCR4 agonists, including SDF-1 polypeptides and SDF-1 polypeptide homologues, may be used in reducing the rate of hematopoietic cell multiplication. Methods of the invention may comprise administration of an effective amount of an CXCR4 agonist to cells selected from the group consisting of hematopoietic stem cells and hematopoietic progenitor cells. Cells may be treated in vitro or in vivo in a patient. A therapeutically effective amount of the CXCR4 agonist may be administered to a patient in need of such treatment. Patients in need of such treatments may include, for example patients requiring bone marrow or peripheral blood stem cell transplantation.Type: ApplicationFiled: February 26, 2002Publication date: August 7, 2003Inventors: Christopher R. Tudan, Ahmed Merzouk, Lakhdar Arab, Geeta Saxena, Connie J. Eaves, Johanne Cashman, Ian Clark-Lewis, Hassan Salari
-
Publication number: 20020165123Abstract: In accordance with various aspects of the invention, CXCR4 agonists, including SDF-1 polypeptides and SDF-1 polypeptide homologues, may be used in reducing the rate of hematopoietic cell multiplication. Methods of the invention may comprise administration of an effective amount of an CXCR4 agonist to cells selected from the group consisting of hematopoietic stem cells and hematopoietic progenitor cells. Cells may be treated in vitro or in vivo in a patient. A therapeutically effective amount of the CXCR4 agonist may be administered to a patient in need of such treatment. Patients in need of such treatments may include, for example patients requiring bone marrow or peripheral blood stem cell transplantation.Type: ApplicationFiled: April 12, 2001Publication date: November 7, 2002Inventors: Christopher R. Tudan, Ahmed Merzouk, Lakhdar Arab, Geeta Saxena, Connie J. Eaves, Johanne Cashman, Ian Clark-Lewis, Hassan Salari
-
Publication number: 20020156034Abstract: In accordance with various aspects of the invention, CXCR4 antagonists may be used to treat hematopoietic cells, such as progenitor or stem cells, to promote the rate of cellular multiplication, self-renewal, proliferation or expansion. CXCR4 antagonists may be used therapeutically to stimulate hematopoietic stem/progenitor cell multiplication/self-renewal.Type: ApplicationFiled: May 9, 2001Publication date: October 24, 2002Inventors: Christopher R. Tudan, Ahmed Merzouk, Lakhdar Arab, Geeta Saxena, Connie J. Eaves, Johanne Cashman, Ian Clark-Lewis, Hassan Salari
-
Patent number: 5665346Abstract: The present invention provides human interleukin-8 (IL-8) analogs that are modified in the Glu4 Leu5 Arg6 region, and have a core structure corresponding to the IL-8 (7-51) sequence are provided. These neutrophil binding analogs display altered IL-8 activities that can be exploited for therapeutic and other purposes. Such antagonists include those in which, for example, the Leu5 and/or Arg6 residues are replaced, and in which the Glu4 and/or Leu5 residues are deleted. Also provided are biologically active human interleukin-8 (IL-8) analogs comprising a core sequence that includes IL-8 (1-51), IL-8 (3-51) or IL-8 (4-51). The invention also provides pharmaceutical compositions containing the aforementioned analogs.Type: GrantFiled: September 27, 1994Date of Patent: September 9, 1997Assignee: Research Corporation Technologies, Inc.Inventors: Ian Clark-Lewis, Bernhard Moser
-
Patent number: 5380531Abstract: The present invention relates to liposomal compositions having a concentration gradient which load amino acids and peptides exhibiting weak acid or base characteristics into liposomes. Specifically loaded into liposomes by the methods of the present invention are C-terminal substituted amino acids or peptides. The liposomes are preferably large unilamellar vesicles. The concentration gradient is formed by encapsulating a first medium in the liposomes, said medium having a first concentration of the one or more charged species, and suspending the liposomes in a second medium having a second concentration of the one or more charged species, such as for example a pH gradient. Also disclosed are pharmaceutical preparations comprising such C-terminal substituted amino acids or peptides which have been loaded into the liposomes by the method of the invention.Type: GrantFiled: June 2, 1992Date of Patent: January 10, 1995Assignee: The Liposome Company, Inc.Inventors: Ajoy Chakrabarti, Ian Clark-Lewis, Pieter R. Cullis